Thirty Companies have Accepted to Join IPG Membership

IPGaia, Inc., (“IPG”) operates IPG membership, which was established with the mission of providing pharmaceutical companies with more efficient access to clinical development drug candidates. We are happy to announce today that the number of member companies accepting IPG membership has exceeded thirty domestic and foreign pharmaceutical companies. Ten out of the thirty member companies are global pharmaceutical companies from abroad, and seven of the fifteen top pharmaceutical companies by revenue in the world (according to our research) have accepted to join the IPG membership.

IPG is a platform provider for drug discovery and development in pre-clinical stage, and the company efficiently generates high-quality clinical development candidates from drug discovery seeds. IPG improves the efficiency of the drug discovery and development process for pharmaceutical companies at a lower cost than the industry standard by continuously generating high-quality clinical development candidates from a wide range of drug discovery seeds.

Our “IPG Membership” companies allow them to select multiple IPG programs according to their interests and communicate them to IPG, enhancing the prioritization of the IPG programs.

The contents and progress of IPG programs are available at any time, and after joining the IPG membership, pharmaceutical companies will have the advantage of increasing their opportunities to bring in preclinical stage drug seeds that match their needs. This allows IPG to understand the unique needs of many pharmaceutical companies (customers) and thereby enhance opportunities for out-licensing as well.

Yasunori Yamaguchi, IPG President and CEO, stated as follows: “IPG membership with thirty member companies as of today has great significance in providing a mechanism where pharmaceutical companies can more efficiently access innovative drug discovery and development opportunities.” He continued, “IPG aim to create deliverables with high customer satisfaction by deepening communication with our member companies. Going forward, IPG will continue to expand membership and fulfill our role as a platform provider in the discovery and development of new drugs.”

  Through its future operations, IPG will significantly streamline the cost and speed of R&D activities for pharmaceutical companies. IPG aims to contribute to society by providing solutions to unmet medical needs and reducing medical costs by making less expensive drugs available to people who need them.

English Press Release